EU Approval Recommended for Sarclisa: A Breakthrough Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Sarclisa Recommended for EU Approval by the CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma Positive Recommendation for Sarclisa Paris, November 14, 2024. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for…

Read More

Ready Capital and United Development Funding IV Join Forces: A Definitive Agreement for Acquisition

Ready Capital Announces Acquisition of UDF IV Overview Ready Capital Corporation, a real estate finance company, has entered into a merger agreement to acquire United Development Funding IV (UDF IV), a real estate investment trust that provides capital solutions to residential real estate developers and homebuilders. This acquisition is expected to diversify Ready Capital’s portfolio…

Read More

Innovative, Articulate, and Easy to Follow: Northern Trust Predicts Moderate Global Equity Returns, Strong High-Yield Bond Performance, and Private Credit Strength

Northern Trust Capital Market Assumptions 2025 Edition Introduction Northern Trust recently released its highly anticipated Capital Market Assumptions (CMA) 2025 Edition, providing insights into the global equity performance, bond returns, and trends that will shape markets and the global economy over the next decade. This edition is particularly focused on AI-Enabled Productivity, Navigating the Energy…

Read More